Neurocrine Biosciences announced that its investigational drug, NBI-1117568, achieved the primary endpoint in a Phase 2 clinical trial for the treatment of adults with schizophrenia.

In the study, a 20 mg dose of NBI-1117568 was associated with a significant reduction in symptom severity compared to placebo in adult patients diagnosed with schizophrenia. The company reported that the drug was generally safe and well-tolerated across all doses tested.

Neurocrine Biosciences intends to initiate Phase 3 trials in early 2025.